AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Researchers from Helmholtz Munich and the Technical University of Munich have developed a novel method to track cancer treatment responses in individual cells—without the need for dyes or labels.

In order to produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic ...

Gynecological clear cell cancers (CCCs), very aggressive forms of ovarian and endometrial malignancies, respond poorly to chemotherapy.  The low respo | Cancer ...

The authors proposed two hypotheses: first, that methamphetamine induces neuroinflammation, and second, that it alters neuronal stem cell differentiation. These are valuable hypotheses, and the ...

Molecular glues, tiny molecules that connect one protein to another, are promising targets for pharmaceutical research. By ...

BeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...

A team of US researchers has identified a genetic mutation that increased the risk of humans getting cancer, paving the way ...

Fat isn’t just a guilty pleasure — it’s cancer’s secret weapon. New research from UT Southwestern Medical Center is shedding light on why this is the case.

Fat isn’t just a guilty pleasure — it’s cancer’s secret weapon. New research from UT Southwestern Medical Center is shedding light on why this is the case.

Abstract e14702 Background: All six programmed cell death-1 (PD-1) inhibitors (nivolumab, pembrolizumab, sintilimab, tislelizumab, toripalimab, and camrelizumab) have been used as first-line therapy ...